大黄蟅虫丸抗大鼠免疫性肝纤维化研究  

Experimental Study of Dahuang Zhechong Pills(DHZC)in Treatment of  Immunological Liver Fibrosis in Rast

作　　者：孙克伟[1] 陈翔[1] 刘伟士[1] 谌宁生[1] 褚裕义[1] 谢凤瑛[1] 

机构地区：[1]湖南中医学院第一附属医院

出　　处：《中国中药杂志》1998年第8期497-499,共3页China Journal of Chinese Materia Medica

摘　　要：目的：研究大黄虫丸防治肝纤维化的作用。方法：运用大鼠免疫性肝纤维化模型，观察大黄虫丸对肝组织病理学、肝羟脯氨酸（ＨＹＰ）含量的影响。结果：大黄虫丸预防和治疗试验肝纤维化率分别为７２．７％和７１．２％，而模型组和秋水仙碱组肝纤维化率为９２．３％～１００％，尤其是大黄虫丸治疗试验组肝ＨＹＰ含量下降显著，与模型组比较Ｐ＜０．０５。结论：大黄虫丸有一定的抗肝纤维化作用。Objective:To study the effect of DHZC on liver fibrosis.Method:Immunoinjured fibrosis in rats was induced by bovine serum albumin and DHZC was given during and after the model production respectively. Hepatic collagen contents,pathology of liver and serum hyaluronic acid were measured. Colchicine was used as control.Result:The shows that the liver fibrosis rates of the DHZC treated group during and after the model production were 72.7% and 71.2% respectively, while those of the untreated and colchicine group were 92.3%～100%.Compared with the untreated group,there was a remarkable decrease of hepatic collagen contents in the DHZCtreated rats.Conclusion:DHZC have thus been proved helpful in reversing liver fibrosis to some extent.

关 键 词：大黄Zhe虫丸 肝纤维化 中医药疗法 免疫性 

分 类 号：R259.752[医药卫生—中西医结合]